Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 6;12(5):e052926.
doi: 10.1136/bmjopen-2021-052926.

Study designs for clinical trials applied to personalised medicine: a scoping review

Cecilia Superchi  1 , Florie Brion Bouvier  2 , Chiara Gerardi  3 , Montserrat Carmona  4   5 , Lorena San Miguel  6 , Luis María Sánchez-Gómez  4   5 , Iñaki Imaz-Iglesia  4   5 , Paula Garcia  7 , Jacques Demotes  7 , Rita Banzi  3 , Raphaël Porcher  2 ; PERMIT Group
Collaborators, Affiliations

Study designs for clinical trials applied to personalised medicine: a scoping review

Cecilia Superchi et al. BMJ Open. .

Abstract

Objective: Personalised medicine (PM) allows treating patients based on their individual demographic, genomic or biological characteristics for tailoring the 'right treatment for the right person at the right time'. Robust methodology is required for PM clinical trials, to correctly identify groups of participants and treatments. As an initial step for the development of new recommendations on trial designs for PM, we aimed to present an overview of the study designs that have been used in this field.

Design: Scoping review.

Methods: We searched (April 2020) PubMed, Embase and the Cochrane Library for all reports in English, French, German, Italian and Spanish, describing study designs for clinical trials applied to PM. Study selection and data extraction were performed in duplicate resolving disagreements by consensus or by involving a third expert reviewer. We extracted information on the characteristics of trial designs and examples of current applications of these approaches. The extracted information was used to generate a new classification of trial designs for PM.

Results: We identified 21 trial designs, 10 subtypes and 30 variations of trial designs applied to PM, which we classified into four core categories (namely, Master protocol, Randomise-all, Biomarker strategy and Enrichment). We found 131 clinical trials using these designs, of which the great majority were master protocols (86/131, 65.6%). Most of the trials were phase II studies (75/131, 57.2%) in the field of oncology (113/131, 86.3%). We identified 34 main features of trial designs regarding different aspects (eg, framework, control group, randomisation). The four core categories and 34 features were merged into a double-entry table to create a new classification of trial designs for PM.

Conclusions: A variety of trial designs exists and is applied to PM. A new classification of trial designs is proposed to help readers to navigate the complex field of PM clinical trials.

Keywords: Clinical trial; Precision medicine; Scoping review; Study design.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study selection flow diagram. PERMIT, PERsonalised MedIcine Trials.
See this image and copyright information in PMC

References

    1. Heckman-Stoddard BM, Smith JJ. Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs 2014;30:109–16. 10.1016/j.soncn.2014.03.004 - DOI - PMC - PubMed
    1. Council of the European Union . Notices from European Union institutions, bodies, offices and agencies. OJEU, 2015.
    1. Tajik P, Zwinderman AH, Mol BW, et al. . Trial designs for personalizing cancer care: a systematic review and classification. Clin Cancer Res 2013;19:4578–88. 10.1158/1078-0432.CCR-12-3722 - DOI - PubMed
    1. Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev 2019;73:20–30. 10.1016/j.ctrv.2018.12.003 - DOI - PubMed
    1. Vivot A, Li J, Zeitoun J-D, et al. . Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. Genet Med 2016;18:796–805. 10.1038/gim.2015.165 - DOI - PubMed

Publication types